LU 125950

Drug Profile

LU 125950

Latest Information Update: 30 Jan 2013

Price : $50

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Antineoplastics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 Aug 1996 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 29 Aug 1996 Discontinued-Preclinical for Cancer in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top